Timeline Shifts for Ribon's PARP14 Inhibitor: Atopic Dermatitis

Janus kinase inhibitors for atopic dermatitis: a promising treatment modality - Cartron - 2021 - Clinical and Experimental Dermatology - Wiley Online Library

RBN-3143 – Reducing Th17 and Th2 signaling to treat multiple inflammatory diseases through PARP14 inhibition – Ribon Therapeutics

Pfizer's abrocitinib non-inferior to Sanofi's Dupixent in atopic dermatitis < Pharma < Article - KBR

Intercept Pharmaceuticals Hits a Regulatory Hurdle: Late-stage NASH Trial Terminated

Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis - ScienceDirect

Day 1 Agenda 7th Dermatology Drug Development Summit

Timeline of PARP inhibitor approvals. FDA, Food and Drug

JAK inhibitors in the treatment of atopic dermatitis - Journal of Allergy and Clinical Immunology

Atopic Dermatitis in Children and Adults (31.03.2023)

Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy